NRG-GI008 / CIRCULATE-US — Circulating-tumor-DNA-guided adjuvant chemotherapy in resected stage II–III colon cancer

Phase 2/3 · Colorectal Cancer

Population

Resected stage II–III colon cancer.

Primary Endpoint

Disease-free survival and time to ctDNA clearance

Rationale

Circulating tumor DNA detects microscopic residual disease after colon surgery. CIRCULATE-US tests whether ctDNA can safely de-escalate therapy for negative patients and escalate it for positive ones.

What It Could Change

Could make ctDNA a routine guide for who needs — and how much — adjuvant chemotherapy after colon surgery.